Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0149-2918(08)00192-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Collaboration to transition members to preferred formulary dipeptidyl-peptidase-4 inhibitor.
Am J Manag Care
January 2025
Ascension Borgess Hospital, 345 Naomi St, Plainwell, MI 49080. Email:
Objective: To describe the outcomes of a partnership between a drug plan and pharmacists to switch patients from brand name dipeptidyl-peptidase-4 inhibitors to the generic alogliptin.
Study Design: Single-center, retrospective chart review.
Methods: Clinical pharmacists contacted patients with primary care providers within the health system affiliated with the drug plan to facilitate the switch.
Use of Potentially Nephrotoxic Drugs in Type 2 Diabetes Patients on SGLT2i: A Trajectories Analysis.
Pharmacoepidemiol Drug Saf
February 2025
Division of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Purpose: To characterize trajectories of nephrotoxic potential (NxP) drug use among older adults with Type 2 Diabetes (T2D) treated with SGLT2is and identify associated patient characteristics.
Methods: Using 2012-2019 Medicare data, we selected patients with T2D who filled at least one prescription for SGLT2is. Index date was the date of the first SGLT2i prescription filled.
anti-diabetic potential of medicinal herbs commonly used in the Ayurvedic system of Sri Lanka with comprehensive metabolite profiling of using GC-MS and LC-HRMS.
Nat Prod Res
January 2025
Nutritional Biochemistry Program, National Institute of Fundamental Studies, Kandy, Sri Lanka.
This study assessed the anti-diabetic potential and bioactive constituents of ten Sri Lankan medicinal herbs. Initial screening of aqueous extracts for starch-digesting enzyme inhibition prioritised three plants with notable activity ( ≤ 0.05), for further assessment using methanolic extracts: (PE), (CA), and (HI).
View Article and Find Full Text PDFDiabetes and gut microbiome.
Front Microbiol
January 2025
Institute for Clinical and Experimental Medicine, Diabetes Centre, Prague, Czechia.
Diabetes mellitus represents a significant global health problem. The number of people suffering from this metabolic disease is constantly rising and although the incidence is heterogeneous depending on region, country, economic situation, lifestyle, diet and level of medical care, it is increasing worldwide, especially among youths and children, mainly due to lifestyle and environmental changes. The pathogenesis of the two most common subtypes of diabetes mellitus, type 1 (T1DM) and type 2 (T2DM), is substantially different, so each form is characterized by a different causation, etiology, pathophysiology, presentation, and treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!